These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30670049)

  • 21. miRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1.
    Ashizawa M; Okayama H; Ishigame T; Thar Min AK; Saito K; Ujiie D; Murakami Y; Kikuchi T; Nakayama Y; Noda M; Tada T; Endo H; Fujita S; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2019 Jun; 17(6):1403-1413. PubMed ID: 30872332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.
    Mehrvarz Sarshekeh A; Alshenaifi J; Roszik J; Manyam GC; Advani SM; Katkhuda R; Verma A; Lam M; Willis J; Shen JP; Morris J; Davis JS; Loree JM; Lee HM; Ajani JA; Maru DM; Overman MJ; Kopetz S
    Clin Cancer Res; 2021 Mar; 27(6):1663-1670. PubMed ID: 33414133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression.
    Peng K; Liu Y; Liu S; Wang Z; Zhang H; He W; Jin Y; Wang L; Xia X; Xia L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1043-1058. PubMed ID: 38315285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
    BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Checkpoints as a Target for Colorectal Cancer Treatment.
    Passardi A; Canale M; Valgiusti M; Ulivi P
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy.
    Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F
    Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6.
    Jiang L; Zhao XH; Mao YL; Wang JF; Zheng HJ; You QS
    J Exp Clin Cancer Res; 2019 Nov; 38(1):465. PubMed ID: 31718693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer.
    Inamori K; Togashi Y; Fukuoka S; Akagi K; Ogasawara K; Irie T; Motooka D; Kobayashi Y; Sugiyama D; Kojima M; Shiiya N; Nakamura S; Maruyama S; Suzuki Y; Ito M; Nishikawa H
    JCI Insight; 2021 May; 6(9):. PubMed ID: 33755600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-suppressive miR-26a and miR-26b inhibit cell aggressiveness by regulating FUT4 in colorectal cancer.
    Li Y; Sun Z; Liu B; Shan Y; Zhao L; Jia L
    Cell Death Dis; 2017 Jun; 8(6):e2892. PubMed ID: 28640257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.
    Pfuderer PL; Ballhausen A; Seidler F; Stark HJ; Grabe N; Frayling IM; Ager A; von Knebel Doeberitz M; Kloor M; Ahadova A
    Br J Cancer; 2019 Aug; 121(5):395-404. PubMed ID: 31358939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MHC class III lymphocyte antigens 6 as endogenous immunotoxins: Unlocking immunotherapy in proficient mismatch repair colorectal cancer.
    Giordano G; Pancione M
    WIREs Mech Dis; 2024; 16(1):e1631. PubMed ID: 37818781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer.
    Thomas J; Leal A; Overman MJ
    Clin Colorectal Cancer; 2020 Jun; 19(2):73-81. PubMed ID: 32173280
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation.
    Gröschl B; Bettstetter M; Giedl C; Woenckhaus M; Edmonston T; Hofstädter F; Dietmaier W
    Int J Cancer; 2013 Apr; 132(7):1537-46. PubMed ID: 22965873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
    Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
    Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-L1 protein expression in tumour cells and immune cells in mismatch repair protein-deficient and -proficient colorectal cancer: the foundation study using the SP142 antibody and whole section immunohistochemistry.
    El Jabbour T; Ross JS; Sheehan CE; Affolter KE; Geiersbach KB; Boguniewicz A; Ainechi S; Bronner MP; Jones DM; Lee H
    J Clin Pathol; 2018 Jan; 71(1):46-51. PubMed ID: 28667193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
    Çakır E; Saygın İ; Ercin ME
    Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.